Corbion stock
CRBN.ASAMSCorbion N.V., Basic MaterialsISIN NL0010583399
66Score 66 out of 100, Neutral
Price and trend
81 / 100
Price history
+45% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 29% above it.
Since December 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 65).
The price is 3.6% below its 52-week high. Largest decline in 20 years: 72% (May 2007 to March 2009).
Chart figures for advanced users
- SMA 50$26.30
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$22.92
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)65
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$19.75
- The lowest closing price of the last twelve months.
- Resistance$30.54
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Corbion N.V. belongs to the Chemicals (Specialty) industry (Netherlands) and, with a market value of $1.7B, is number 85 of 106 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $1.4B (down 1.6% year on year) and earnings of $82.89M (down 61.1%).
- For fiscal 2026, analysts expect on average revenue of $1.44B (up 2.7%) and adjusted earnings per share of $1.52 (up 6.4%).
Show more
- MEQIRI Score 66 out of 100 (Neutral): rank 119 of 461 in Basic Materials, median 57.
- The P/E is 25 (Chemicals (Specialty) median 24.4, own median of recent years 19.7).
- Our model puts fair value at $42.00, with the price 30% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Below fair valuePrice 30% below the fair value of $42.00.Valuation 74
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 77
- Reliable dividendNo dividend cut for 10 years.Capital allocation 52
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are momentum and technical analysis, while growth and profitability hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- cyclical sector (energy or materials), as a group, crashed more often in the backtest
What lowers it
- stable momentum
- price near its 52-week high
Valuation
Valuation signal
Significantly undervaluedIn our model the price counts as cheap below $32.31 and expensive above $60.00 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $55.18 (cash-flow model) and $28.82 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 7.3%. At 8.3% the fair value would be $37.06, at 6.3% it would be $49.45.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (24.4).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue fell 3.4% on the twelve months before. Revenue has grown solidly since 2012, at about 4% per year. From 2012 revenue only includes continuing operations, sold or discontinued divisions have been reclassified. Earlier years are not comparable and not shown, and the margins for 2012 are not measured.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 26%, operating 9%, net 6%. From 2012 revenue only includes continuing operations, sold or discontinued divisions have been reclassified. Earlier years are not comparable and not shown, and the margins for 2012 are not measured.
Debt & balance sheet
latest quarterModerate debt, and interest is adequately covered.
Earnings
- Next earnings
- 26 Feb 2027in 105 days
- Last reported
- 31 Jul 2026EPS reported $0.57 (expected $0.54)above expectations
Analyst estimates
Analysts have raised their 2027 earnings estimate by 6.1% since 15 Oct 2026.
- Earnings per share
- $1.52+4.3%
- Revenue
- $1.44B+0.6%
- Earnings per share
- $1.88+6.1%
- Revenue
- $1.54B+2.3%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook lowered
Share price after the results: +0.6%Adjusted EBITDA margin outlook refined down to above 16% from about 17%; organic sales growth of 3% to 6% and free cash flow of EUR 85 million to EUR 90 million maintained.
“For the full year 2026, we maintain our organic sales growth outlook of 3% to 6%.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 31 Jul 2026 (fiscal Q2 2026), read by AI.
What happened at Corbion
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
461 rated companies in Basic Materials
- This company
- 66
- Sector median
- 57
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Chemicals (Specialty)
The next larger and next smaller companies by market value
- ChemoursCC $2.01B32
- InnospecIOSP $1.95B64
- Minerals TechnologiesMTX $1.92B45
- VERBIO Vereinigte BioEnergieVBK.DE $1.81B52
- BorregaardBRG.OL $1.64B63
- Stepan CoSCL $1.51B51
- Industrie De NoraDNR.MI $1.32B45
- ElkemELK.OL $1.22B50
ETFs that hold Corbion
Held by 13 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| UBS MSCI EMU Small Cap UCITS ETF EUR disUEFD | 0.31% | 0.28% | €630.46M |
| State Street SPDR MSCI Europe Small Cap Value Weighted UCITS ETF EUR AccZPRX | 0.12% | 0.30% | €813.64M |
| Xtrackers MSCI Europe Small Cap UCITS ETF 1CXXSC | 0.09% | 0.30% | €3.45B |
Show 5 more
| Amundi MSCI EMU Small Cap ESG Broad Transition UCITS ETF DISTLGWU | 0.07% | 0.40% | €580.62M |
| UBS MSCI EMU Select Factor Mix UCITS ETF EUR accUIQN | 0.05% | 0.34% | €16.96M |
| Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF DistX026 | 0.03% | 0.23% | €321.86M |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.02% | 0.45% | €1.54B |
| Avantis Global Small Cap Value UCITS ETFAVWS | 0.02% | 0.39% | €1.49B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 3 Oct 2025)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.